share_log

和黄医药(00013.HK):将于2024年欧洲血液协会(EHA)年会公布索乐匹尼布 (sovleplenib) ESLIM-01 III期研究以及血液恶性肿瘤项目数据

Hehuang Pharmaceutical (00013.HK): Will announce data on the 2024 European Hematology Association (EHA) ESLIM-01 phase III study and hematological malignancy project data

Gelonghui Finance ·  May 17 08:28

Gelonghui, May 17丨Hewang Pharmaceutical (00013.HK) announced today that it will announce the top line and subgroup results of the solepinib ESLIM-01 phase III study, as well as the latest and updated clinical data on innovative exploratory hematologic malignancy therapies HMPL-306, HMPL-760, and tazostat (tazostemetat) at the European Hematology Association (“EHA”) annual meeting to be held in Madrid and online from June 13 to June 16, 2024.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment